Vanguard Global Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.78M Buy
88,334
+8,000
+10% +$144K ﹤0.01% 1333
2026
Q2
$1.39M Sell
80,334
-26,220
-25% -$359K ﹤0.01% 1531
2026
Q1
$1.32M Buy
+106,554
New +$1.43M ﹤0.01% 1461

Other funds holding AMRX

Vanguard Global Advisers's AMRX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Amneal Pharmaceuticals (AMRX) stake by 10% in Q3 2026, buying an estimated $144K and bringing the position to 88,334 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1333.

Vanguard Global Advisers first reported a position in AMRX in Q1 2026 and has held it in 3 quarters since. 334 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Vanguard Global Advisers held 88,334 shares of Amneal Pharmaceuticals worth $1.78M as of Q3 2026.
  • Vanguard Global Advisers bought 8,000 Amneal Pharmaceuticals shares in Q3 2026, an estimated $144K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1333 holding.
  • Vanguard Global Advisers first reported a position in Amneal Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 334 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.